Fedratinib was very efficient in reducing erythroid hyperplasia in the PV/PPMF models as shown by the reduced number of MEP, spleen erythroblasts, circulating reticulocytes and RBC, confirming JAK2 inhibition as an option in PV treatment 9. This evidence concerns the gene JAK2 and acquired polycythemia vera.